Fondaparinux as the sole anticoagulant during PCI has been associated with catheter thrombosis, and use of an anticoagulant with anti-IIa activity is recommended when patients treated with fondaparinux undergo PCI.313 315 One suggested regimen is UFH 85 IU/kg IV if no GP IIb/IIIa inhibitor is used and 60 IU/kg IV if a GP IIb/IIIa inhibitor is used with UFH dosing based on the target-activated clotting Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e375 5.2. Timing of Urgent CABG in Patients With NSTE-ACS in Relation to Use of Antiplatelet Agents: Recommendations Class I 1. Non enteric-coated aspirin (81 mg to 325 mg daily) should be administered preoperatively to patients (Level of Evidence: B) 2. In patients referred for elective CABG, clopidogrel and ticagrelor should be discontinued for at least (Level of Evidence: B) and prasugrel for at least 7 days before surgery.8,414 (Level of Evidence: C) 3. In patients referred for urgent CABG, clopidogrel and ticagrelor should be discontinued for at least 24 hours to reduce major bleeding.8,412,415 417 (Level of Evidence: B) 4. In patients referred for CABG, short-acting intrave- nous GP IIb/IIIa inhibitors (eptifibatide or tirofiban) should be discontinued for at least 2 to 4 hours before and abciximab for at least 12 hours be- fore to limit blood loss and transfusion.389 (Level of Evidence: B) Class IIb 1. In patients referred for urgent CABG, it may be reasonable to perform surgery less than 5 days after clopidogrel or ticagrelor has been discontinued and less than 7 days after prasugrel has been discontin- ued. 